Spots Global Cancer Trial Database for clear cell renal cell carcinoma (ccrcc)
Every month we try and update this database with for clear cell renal cell carcinoma (ccrcc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | NCT00142415 | Metastatic Rena... | 111-In-DOTA-cG2... 177-Lu-DOTA-cG2... | 18 Years - | Ludwig Institute for Cancer Research | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | NCT03972657 | Metastatic Cast... Clear Cell Rena... | REGN5678 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | NCT00142415 | Metastatic Rena... | 111-In-DOTA-cG2... 177-Lu-DOTA-cG2... | 18 Years - | Ludwig Institute for Cancer Research | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | NCT02002312 | Metastatic Clea... | Lu-177-DOTA-gir... | 18 Years - | Radboud University Medical Center | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
